Patents by Inventor Taishi Onodera

Taishi Onodera has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11517616
    Abstract: The present invention addresses the issue of providing a norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration which vaccine can readily immunize the target cells, an associated product of a molecular needle serving as an active ingredient of the vaccine, and a production method for the associated product. The invention provides a norovirus component vaccine containing, as an active ingredient, an associated product including a hexamer formed through bonding of two molecules of a trimer of a molecular needle represented by the following formula (1). W-L1-Xn—Y (1) [wherein W represents an amino acid sequence of P domain of the capsid protein of norovirus as an immunogen; L1 represents a first linker sequence having 0 to 100 amino acids; X represents an amino acid sequence represented by SEQ ID NO: 1; Y represents an amino acid sequence of a cell introduction domain; n is an integer of 1 to 3].
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: December 6, 2022
    Assignees: Denka Company Limited, TOKYO INSTITUTE OF TECHNOLOGY, THE KITASATO INSTITUTE, DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES
    Inventors: Takafumi Ueno, Kengo Yoshikawa, Megumi Mano, Kazuhiko Katayama, Motohiro Miki, Reiko Todaka, Yoshimasa Takahashi, Taishi Onodera
  • Publication number: 20210299240
    Abstract: The present invention addresses the issue of providing a norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration which vaccine can readily immunize the target cells, an associated product of a molecular needle serving as an active ingredient of the vaccine, and a production method for the associated product. The invention provides a norovirus component vaccine containing, as an active ingredient, an associated product including a hexamer formed through bonding of two molecules of a trimer of a molecular needle represented by the following formula (1). W-L1-Xn—Y (1) [wherein W represents an amino acid sequence of P domain of the capsid protein of norovirus as an immunogen; L1 represents a first linker sequence having 0 to 100 amino acids; X represents an amino acid sequence represented by SEQ ID NO: 1; Y represents an amino acid sequence of a cell introduction domain; n is an integer of 1 to 3].
    Type: Application
    Filed: October 19, 2017
    Publication date: September 30, 2021
    Applicants: DENKA COMPANY LIMITED, TOKYO INSTITUTE OF TECHNOLOGY, THE KITASATO INSTITUTE, JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES
    Inventors: Takafumi UENO, Kengo YOSHIKAWA, Megumi MANO, Kazuhiko KATAYAMA, Motohiro MIKI, Reiko TODAKA, Yoshimasa TAKAHASHI, Taishi ONODERA
  • Patent number: 9018245
    Abstract: The purpose of the present invention is to elucidate a relationship between deregulation of signaling by CD22 and a rapid response of B cells by IgG-BCR and the like, and to provide a method capable of inducing a rapid immune response and defending against infection instead of vaccine. The present invention relates to a method for promoting an immune response causing such a strong proliferation of clones and production of a large amount of antibody-producing cells as those seen in the memory immune response even in the naive B cells expressing IgM-BCR and IgD-BCR by inhibiting the CD22 function in B cells; and to a method for screening a substance capable of promoting the immune response based on a change in the CD22 function in B cells.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: April 28, 2015
    Assignee: Japan Science and Technology
    Inventors: Takeshi Tsubata, Taishi Onodera
  • Publication number: 20100063130
    Abstract: The purpose of the present invention is to elucidate a relationship between deregulation of signaling by CD22 and a rapid response of B cells by IgG-BCR and the like, and to provide a method capable of inducing a rapid immune response and defending against infection instead of vaccine. The present invention relates to a method for promoting an immune response causing such a strong proliferation of clones and production of a large amount of antibody-producing cells as those seen in the memory immune response even in the naive B cells expressing IgM-BCR and IgD-BCR by inhibiting the CD22 function in B cells; and to a method for screening a substance capable of promoting the immune response based on a change in the CD22 function in B cells.
    Type: Application
    Filed: December 21, 2007
    Publication date: March 11, 2010
    Applicant: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Takeshi Tsubata, Taishi Onodera